BioStock: Respiratorius turns its focus to COPD and severe asthma

26 October 2020 - 10:28

Much has gone the way of Respiratorius’ main candidate, the cancer drug VAL001. Following the EMA’s recommendation to go directly to phase III, they are now looking for a partner to reach an agreement and take the candidate further. Thus, more operational focus is now being placed on the next candidate in the development queue, RESP9000 for the treatment of COPD and severe asthma.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

Provided by: Cision
Spotlight (Sweden)
Respiratorius AB
Respiratorius is a research company. Today, the company is mainly focused on development of new drug candidates for the treatment of chronic obstructive pulmonary disease (COPD), asthma and cancer. Additionally, the company focuses on project development in the area of cardiovascular diseases. The company was formed in 1999 as a spin-off from Lund University. The company is based in Lund....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date